PO.ET05.02 · 实验与分子治疗

建立用于测量抗体药物偶联物(ADC)旁观者效应的乳腺癌实验模型

Establishment of experimental model for measuring antibody-drug conjugate (ADC) bystander effects in breast cancer

海报缩略图:建立用于测量抗体药物偶联物(ADC)旁观者效应的乳腺癌实验模型
编号 2935 展板 12 时间 4/20 02:00–05:00 区域 Section 11 主讲 Hyunmyoung Yun, BS;MS;PhD
分会场 Cellular Responses to Anticancer Drugs
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Hyunmyoung Yun1, Won-Ji Ryu1, Hyein Jung1, Tae Yeong Kim1, Cheol-Hwa Hong1, Yumi Hwang1, Hyun Ju Han1, Geon-Uk Kim1, Seo Young Lee1, Kyoo Hyun Kim2, Min Hwan Kim2, Gun Min Kim2, Joo Hyuk Sohn2

1Avison Biomedical Research Center, Yonsei University College of Medicine SBSI, Seoul, Korea, Republic of,2Department of Internal Medicine, Yonsei University College of Medicine SBSI, Seoul, Korea, Republic of

摘要 Abstract

中文摘要
靶向HER2和TROP2的抗体药物偶联物(ADC)现已成为乳腺癌治疗的支柱。配备可裂解连接子-载荷系统的ADC可通过旁观者效应杀伤非靶点表达的癌细胞,该效应受抗体内化及连接子-载荷复合物的溶酶体降解的影响。我们首先评估了靶向HER2的ADC trastuzumab deruxtecan(T-DXd)在一组乳腺癌细胞系中的IC50值。HER2蛋白表达水平与对T-DXd的敏感性高度相关,证实HER2靶点表达是个体反应的主要决定因素。接下来,我们通过将MCF7(低HER2)与SK-BR-3(HER2+)细胞共培养来评估旁观者效应的存在。T-DXd成功地诱导了MCF7中caspase-3的激活。利用共培养实验中的观察结果,我们建立了一个定量共培养模型来测量ADC介导的旁观者活性的大小。在该模型中,我们对TNBC细胞系MDA-MB-231(HER2阴性)进行工程化改造,使其稳定表达EGFP,以便与SK-BR3(HER2+)共培养。用pHrodo Red标记T-DXd以可视化乳腺癌细胞中溶酶体-ADC的接触,并通过gamma-H2AX染色评估DNA损伤。我们观察到T-DXd选择性地在SK-BR-3细胞中发生内化并与溶酶体共定位,而在MDA-MB-231细胞中则没有。然而,在EGFP标记的MDA-MB-231细胞中检测到gamma-H2AX激活,提示载荷DXd通过旁观者效应发生传播。最后,我们利用靶向panel NGS数据,对50例接受ADC治疗的乳腺癌患者进行基因组分析,以识别可能与旁观者活性相关的遗传因素。通过Cox回归分析,NOTCH1、NOTCH2和NF1的改变与ADC治疗下较差的无进展生存相关,而这些基因与溶酶体和自噬调控有关。总之,这些发现凸显了ADC的抗癌疗效在很大程度上受旁观者效应影响,并强调需要更深入地研究遗传因素如何调节这一过程。
查看英文原文 English abstract
Antibody-drug conjugates (ADCs) targeting HER2 and TROP2 are now a mainstay of breast cancer therapeutics. ADCs equipped with cleavable linker-payload systems can kill non-target-expressing cancer cells through a bystander effect, which is influenced by antibody internalization and lysosomal degradation of the linker-payload complex. We first evaluated the IC 50 values of the HER2-targeting ADC trastuzumab deruxtecan (T-DXd) across a panel of breast cancer cell lines. HER2 protein expression levels correlated well with sensitivity to T-DXd, confirming that HER2 target expression is a major determinant of individual response. We next assessed the presence of bystander effect by co-culturing of MCF7 (low-HER2) with SK-BR-3 (HER2+) cells in culture. T-DXd successfully induced caspase-3 activation in MCF7. Leveraging observation in the co-culture experiment, we established a quantitative co-culture model to measure the magnitude of ADC-mediated bystander activity. In this model, we engineered the TNBC cell line MDA-MB-231 (HER2-null) to stably express EGFP to be co-cultured with SK-BR3 (HER2+). T-DXd was labeled with pHrodo Red to visualize lysosome-ADC contact in breast cancer cells, and DNA damage was assessed by gamma-H2AX staining. We observed internalization and co-localization to lysosome of T-DXd in selectively in SK-BR-3 cells, but not in MDA-MB-231 cells. Whereas, gamma-H2AX activation were detected in EGFP-tagged MDA-MB-231 cells, suggesting propagation of payload DXd via bystander effect. Finally, we performed genomic analyses to identify genetic factors potentially associated with bystander activity in 50 breast cancer patients treated with ADCs using targeted-panel NGS data. Alterations in NOTCH1, NOTCH2, and NF1 were associated with poor progression-free survival under ADC treatment by Cox regression analysis, and these genes are implicated in lysosomal and autophagy regulation. Collectively, these findings highlight that the anticancer efficacy of ADCs is substantially influenced by the bystander effect and underscore the need for deeper investigation into how genetic factors modulate this process.
利益披露 Disclosure
H. Yun, None.. W. Ryu, None.. H. Jung, None.. T. Kim, None.. C. Hong, None.. Y. Hwang, None.. H. Han, None.. G. Kim, None.. S. Lee, None.. K. Kim, None.. M. Kim, None.. G. Kim, None.. J. Sohn, None.

← 返回 AACR 2026 检索